If you or a loved one is in immediate crisis: call 988 (Suicide & Crisis Lifeline) or 1-800-662-HELP (SAMHSA National Helpline). This page is informational and not a replacement for medical advice. Decisions about medication for opioid use disorder require consultation with a qualified prescriber.
Decision Guide · Updated May 2026
Cocaine Use Disorder Treatment
vs
Methamphetamine Use Disorder Treatment
Cocaine vs Methamphetamine Treatment
Compare Cocaine Use Disorder Treatment and Methamphetamine Use Disorder Treatment across 12 decision points — cost, evidence, named criteria for choosing each option.
Last reviewed May 12, 2026
SAMHSA & NIDA sourced
12 data points
10 FAQ
6 sources
Talk to a licensed clinical advisor
- Free & confidential
- 24/7 availability
- Insurance verified in 5 min
- HIPAA-compliant
- No pressure, just answers
Quick Verdict
·
~30 sec read
Reviewed by RehabHive Editorial Team · Last updated May 12, 2026
Neither cocaine nor methamphetamine has FDA-approved pharmacotherapy — both rely on behavioral interventions, primarily contingency management and CBT. Methamphetamine causes longer withdrawal (10-14 days acute vs 5-7 for cocaine) and slower neural recovery, but treatment frameworks are similar. The SAMHSA MATRIX Model is the established protocol for stimulant use disorder; contingency management with the January 2025 CMS expansion to $750/year incentive cap is the most evidence-based intervention. NIDA research shows 117 overdose deaths prevented per 1,000 CM-treated meth patients annually. Both substances pose growing fentanyl-contamination overdose risk in 2024-2026.
Also comparing
Other treatment comparisons
I
Inpatient vs Outpatient Rehab
Inpatient vs outpatient rehab 2026: ASAM levels, cost ($15k-30k vs $5k-10k), duration, success rates, when to choose each. Evidence-based decision guide.
C
CBT vs DBT Therapy
M
Methadone vs Suboxone for Opioid Use Disorder
Methadone vs Suboxone (buprenorphine) for opioid use disorder 2026: efficacy, overdose risk, access, cost compared. Evidence-based MOUD guide with sources.
3
30-Day vs 90-Day Rehab
30-day vs 90-day rehab 2026: NIDA outcome research, $15k-25k vs $30k-60k cost, insurance approval, who needs longer. Evidence-based duration decision.
Save / Send
Email
Side-by-side comparison (12 decision points)
| Factor | Cocaine Use Disorder Treatment | Methamphetamine Use Disorder Treatment |
|---|---|---|
| Acute Withdrawal Duration | 5-7 days | 10-14 days |
| Protracted Withdrawal (PAWS) | Weeks to months (lower severity) | Months (higher severity, anhedonia common) |
| FDA-Approved Medications | None | None |
| First-Line Treatment | CM + CBT | MATRIX Model (CM + CBT + family + 12-step) |
| Contingency Management Cap (CMS 2025) | $750/patient/year | $750/patient/year |
| Stimulant-Induced Psychosis | Less common | More common, can persist weeks |
| Medical Complications | Cardiac (MI, stroke), nasal damage | Dental decay, dermatologic, cardiomyopathy |
| Polysubstance Pattern | Often with alcohol (cocaethylene risk) | Often with opioids (overdose risk) or polysubstance |
| Geographic Concentration | Urban historically | Rural and Western U.S. |
| Fentanyl Contamination Risk | Growing — 5-10% supply estimated | Growing — 5-10% supply estimated |
| Insurance Coverage | Same SUD benefits under MHPAEA | Same SUD benefits under MHPAEA |
| Treatment Duration | 12 weeks IOP typical | 16 weeks MATRIX IOP standard |
Pros and cons
Cocaine Use Disorder Treatment
Pros
- <strong>Shorter withdrawal duration.</strong> Cocaine withdrawal acute phase 5-7 days vs methamphetamine 10-14 days. Cocaine crash typically resolves within 1-2 weeks; sleep, appetite, and energy return faster.
- <strong>Faster initial neural recovery.</strong> Cocaine affects dopamine release mechanisms; methamphetamine causes more sustained dopamine and serotonin disruption. Initial functional recovery faster for cocaine users.
- <strong>CM and CBT evidence base strongest.</strong> Contingency management and CBT have been studied longest for cocaine (1990s onward). NIDA meta-analyses show CM reduces cocaine use rapidly; CBT effects persist months after treatment.
- <strong>Lower geographic concentration.</strong> Cocaine use historically concentrated in urban areas with established treatment infrastructure. Methamphetamine has expanded rapidly in rural areas with limited specialized treatment.
- <strong>Less psychiatric comorbidity typical.</strong> Cocaine users have somewhat lower rates of stimulant-induced psychosis and methamphetamine-related dental and dermatologic complications.
- <strong>Polysubstance pattern often involves alcohol/cannabis.</strong> Cocaine + alcohol use generates cocaethylene (a more cardiotoxic metabolite). Treatment addresses both simultaneously with established polysubstance protocols.
Cons
- <strong>No FDA-approved medications.</strong> Despite decades of research, no medication is FDA-approved for cocaine use disorder. Off-label use of bupropion, topiramate, naltrexone explored but no medication has consistent efficacy.
- <strong>High relapse rates.</strong> Cocaine has among the highest relapse rates of any substance — 60-80% within 12 months without sustained treatment. Behavioral interventions help but limits exist without pharmacotherapy.
- <strong>CM effects subside post-treatment.</strong> Contingency management rapidly reduces use during active treatment but effects diminish after incentives stop. Sustained CBT or maintenance contingency programs needed for long-term outcomes.
- <strong>Cocaethylene risk with alcohol.</strong> Cocaine + alcohol generates cocaethylene metabolite — more cardiotoxic and longer-acting than cocaine alone. Treatment must address combined polysubstance use.
Methamphetamine Use Disorder Treatment
Pros
- <strong>MATRIX Model framework.</strong> SAMHSA MATRIX Model is a manualized 16-week IOP protocol developed specifically for stimulant use disorder. Evidence-based; widely implemented; available in Spanish and culturally-adapted versions.
- <strong>Contingency management highest impact.</strong> 2024-2026 research: 117 overdose deaths prevented per 1,000 CM-treated meth patients annually. Incremental cost-effectiveness ratio $9,830/QALY — highly cost-effective per WHO threshold.
- <strong>Federal CM expansion 2025.</strong> CMS January 2025 increased maximum annual CM incentive cap to $750/patient (from $75 previously). Removes major barrier to evidence-based meth treatment scaling.
- <strong>Treatment urgency recognized.</strong> Meth-related deaths surged 2018-2024 (CDC data). Federal and state funding for meth-specific treatment has expanded; SAMHSA grants prioritize stimulant use disorder programs.
- <strong>Rural treatment expansion.</strong> New telehealth-delivered MATRIX Model and CM programs address rural meth crisis. SAMHSA grants fund mobile treatment units in high-meth-prevalence rural counties.
- <strong>Co-occurring HIV and HCV care integration.</strong> Meth use linked to higher HIV/HCV transmission via injection and sexual risk; meth treatment programs increasingly integrate HIV testing, PrEP, and HCV care.
Cons
- <strong>No FDA-approved medications.</strong> Methamphetamine use disorder also lacks FDA-approved pharmacotherapy. Mirtazapine, naltrexone + bupropion combinations showed promise in trials but not FDA-approved.
- <strong>Longer protracted withdrawal.</strong> Meth post-acute withdrawal (PAWS) can persist months — anhedonia, cognitive impairment, sleep dysregulation. Higher early-recovery relapse risk than cocaine.
- <strong>Higher psychiatric comorbidity.</strong> Meth-induced psychosis can persist weeks-to-months post-cessation. Higher rates of paranoia, hallucinations, formication ("crank bugs") complicating treatment.
- <strong>Medical complications.</strong> Meth-related medical complications: severe dental decay ("meth mouth"), dermatologic lesions, cardiomyopathy, stroke, and neurocognitive impairment. Treatment integrates medical and dental care.
- <strong>Geographic concentration in rural areas.</strong> Meth is concentrated in rural areas with limited specialized treatment infrastructure. Patients often must travel for evidence-based MATRIX Model or contingency management programs.
When to choose each option
Named decision criteria for matching your specific situation to the right option.
When to choose Cocaine Use Disorder Treatment
Primary indicators
- Cocaine-only or cocaine + alcohol use
- Powder cocaine or crack cocaine use
- Shorter use history
Additional considerations
- No stimulant-induced psychosis
- Lower psychiatric comorbidity
- Access to CM + CBT programs
When to choose Methamphetamine Use Disorder Treatment
Best-fit scenarios
- Methamphetamine use (smoked, injected, snorted, oral)
- Polysubstance including meth
- Meth-induced psychosis history
Further considerations
- Severe medical complications (dental, cardiac, dermatologic)
- Rural area with meth crisis
- Want MATRIX Model 16-week IOP structure
Cost & financial impact
Pricing ranges with cited sources (SAMHSA TIP, MEPS, AHRQ, KFF).
Stimulant treatment cost structure
Stimulant SUD treatment (cocaine or methamphetamine) costs comparable to other SUDs. 12-week IOP: $3,000-$8,000 with insurance copay typical; $5,000-$12,000 self-pay. 16-week MATRIX Model IOP: $4,000-$10,000 with insurance; $7,000-$15,000 self-pay. Residential rehab: $20,000-$45,000 for 30 days mid-tier with insurance; $30,000-$60,000 self-pay.
Contingency management costs
CMS January 2025 expansion raised annual CM incentive cap to $750/patient (from $75). Most patients receive gift cards or vouchers at $5-$20 per negative urine drug screen over 12-16 weeks. Total CM cost per patient: $250-$750/year. CM is among the most cost-effective SUD interventions per HHS analysis — incremental cost-effectiveness ratio $9,830/QALY for meth, well below WHO cost-effective threshold ($50,000/QALY).
Insurance coverage parameters
Medicaid covers MATRIX Model and CM under SUD benefit at $0 copay typical; commercial insurance covers under MHPAEA with copay $30-$60 per session. Medicare covers MATRIX Model components but CM coverage variable until full CMS implementation rollout (2025-2026). VA covers MATRIX Model + CM for veterans with meth or cocaine use disorder.
Our verdict
Choose Cocaine Use Disorder Treatment if...
cocaine use disorder — typically shorter and less severe withdrawal, faster brain recovery, contingency management + CBT first-line per NIDA
Learn more about Cocaine Use Disorder Treatment →Choose Methamphetamine Use Disorder Treatment if...
methamphetamine use disorder — longer withdrawal (10-14 days acute, weeks for protracted), slower neural recovery, MATRIX Model first-line per SAMHSA
Learn more about Methamphetamine Use Disorder Treatment →Still not sure which is right for you?
The level of care is a clinical decision based on addiction severity, withdrawal risk, and your home situation — not just personal preference. A free, confidential 2-minute self-assessment can help you gauge severity before you call, and our team can verify your insurance and match you to the right level of care at no cost.
Frequently asked questions
What is the most effective treatment for cocaine addiction?
NIDA evidence: contingency management (CM) plus cognitive-behavioral therapy (CBT) is the most effective treatment for cocaine use disorder. No medication is FDA-approved. CM rapidly reduces use; CBT produces effects persisting months after treatment. Combination approaches (CM during active treatment + CBT for sustained recovery) yield best long-term outcomes.
What is the MATRIX Model?
The MATRIX Model is a 16-week IOP protocol developed by UCLA for stimulant use disorder, particularly methamphetamine. Integrates individual counseling, group therapy, family education, 12-step facilitation, and urine drug testing with contingency management. SAMHSA-published manuals available free at store.samhsa.gov. Widely implemented across federal, state, and private SUD programs.
Is contingency management really effective?
Yes. NIDA and SAMHSA meta-analyses show contingency management among the most effective behavioral interventions for stimulant use disorder. 2026 cost-effectiveness analysis estimates 117 overdose deaths prevented per 1,000 CM-treated meth patients annually. CMS January 2025 expansion to $750/year incentive cap reflects federal recognition of CM evidence base.
Why are there no FDA-approved medications for cocaine or meth?
Decades of research have explored dopaminergic agents (bupropion, mazindol), GABAergic (topiramate, baclofen), and others. Some show modest effects in trials but none meet FDA approval threshold (consistent statistically and clinically significant benefit). The stimulant mechanism — direct dopamine release and reuptake blockade — is harder to medication-treat than opioid receptor agonism. Vaccine research ongoing.
Does insurance cover stimulant addiction treatment?
Yes. Under MHPAEA federal parity, insurance must cover stimulant use disorder treatment at parity with medical-surgical benefits. Coverage includes MATRIX Model IOP, residential, contingency management (where implemented), behavioral therapy, and concurrent psychiatric care. Medicare, Medicaid, and commercial insurance all cover.
How long is methamphetamine withdrawal?
Acute methamphetamine withdrawal lasts 10-14 days typically (vs 5-7 for cocaine). Symptoms: severe fatigue, sleep dysregulation, depressed mood, increased appetite, intense cravings. Post-acute withdrawal (PAWS) can persist 6-12 months: anhedonia, cognitive impairment, sleep dysregulation, periodic intense cravings. Sustained recovery treatment essential during PAWS to prevent relapse.
What is meth-induced psychosis?
Methamphetamine use can cause psychosis (paranoia, hallucinations, delusions, formication). Symptoms typically resolve within days-to-weeks of abstinence but can persist longer with chronic use. Some patients develop persistent psychotic disorders. Treatment involves antipsychotic medications acutely, abstinence, and ongoing psychiatric care. Stimulant-induced psychosis is a leading reason for psychiatric hospitalization in meth-prevalent regions.
Can I detox from cocaine or meth at home?
Stimulant withdrawal is rarely life-threatening (unlike alcohol/benzo). Outpatient detox is feasible with medical follow-up. Inpatient setting recommended when: severe psychiatric symptoms (suicidality, psychosis), polysubstance with alcohol/benzo, unsafe home environment, or pregnancy. ASAM Criteria assessment determines appropriate level. Most stimulant detox occurs outpatient with prompt transition to IOP or MATRIX Model.
Is fentanyl in cocaine or meth supply?
Yes, increasingly. DEA 2024 data: 5-10% of cocaine and meth street supply has fentanyl contamination. Polysubstance overdoses (stimulant + fentanyl) drive significant mortality. Harm reduction critical: fentanyl test strips, naloxone availability, not using alone, supervised consumption sites where available. All stimulant patients should be educated on fentanyl contamination risk and naloxone use.
What is "meth mouth"?
"Meth mouth" refers to severe dental decay associated with chronic methamphetamine use. Mechanisms: meth causes xerostomia (dry mouth) reducing protective saliva; vasoconstriction reduces gum blood flow; bruxism (teeth grinding) damages enamel; sugar cravings and poor dental hygiene compound damage. Treatment includes restorative dentistry, oral hygiene support, and ongoing dental care during recovery. Many MATRIX-affiliated programs integrate dental care.
Sources & references
- SAMHSA MATRIX Model: Counselor and Client Manuals — SAMHSA clinical guideline
- NIDA Cocaine Research Reports — NIH research summary
- NIDA Methamphetamine Research Reports — NIH research summary
- HHS ASPE: Contingency Management for SUD Treatment — Federal policy analysis
- CMS Contingency Management Expansion 2025 — CMS regulation
- CDC Stimulant Use and Overdose Data — Federal data
Was this comparison helpful?
Need help deciding?
Free, confidential guidance from licensed advisors to help you choose between Cocaine Use Disorder Treatment and Methamphetamine Use Disorder Treatment.
Last reviewed: May 12, 2026 • Sourced from SAMHSA, NIDA, peer-reviewed literature • Reviewed by RehabHive Editorial Team • Editorial policy
